6/1/07 Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Saturday, June 30, 2007

Quality of Life for Patients With Epithelial Ovarian Cancer



Quality of Life for Patients With Epithelial Ovarian Cancer

Cancer genetic risk assessment for individuals at risk of familial breast cancer



Cancer genetic risk assessment for individuals at risk of familial breast cancer

Gynecologic Cancer Prevention in Lynch Syndrome/Hereditary Nonpolyposis Colorectal Cancer Families -- Chen et al. 110 (1): 18 -- Obstetrics & Gynecolo



Gynecologic Cancer Prevention in Lynch Syndrome/Hereditary Nonpolyposis Colorectal Cancer Families -- Chen et al. 110 (1): 18 -- Obstetrics & Gynecology

Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations -- Kadouri et al. 44 (7): 467 -- Journal of Medical Genetics



Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations -- Kadouri et al. 44 (7): 467 -- Journal of Medical Genetics

2007 Timing of Referral to Hospice and Quality of Care: Length of Stay and Bereaved Family Members' Perceptions of the Timing of Hospice Referral



JPSM_Late-Referrals_2007.pdf (application/pdf Object)

Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer -- Mutch et



Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer -- Mutch et al. 25 (19): 2811 -- Journal of Clinical Oncology

Friday, June 29, 2007

Changes in and Prognostic Value of Hormone Receptor Status in a Series of Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy -- Tac



Changes in and Prognostic Value of Hormone Receptor Status in a Series of Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy -- Tacca et al. 12 (6): 636 -- The Oncologist

Efficacy and Safety of Every-2-Week Darbepoetin Alfa in Patients with Anemia of Cancer: A Controlled, Randomized, Open-Label Phase II Trial -- Charu e



Efficacy and Safety of Every-2-Week Darbepoetin Alfa in Patients with Anemia of Cancer: A Controlled, Randomized, Open-Label Phase II Trial -- Charu et al. 12 (6): 727 -- The Oncologist

Amifostine: The First Selective-Target and Broad-Spectrum Radioprotector -- Kouvaris et al. 12 (6): 738 -- The Oncologist



Amifostine: The First Selective-Target and Broad-Spectrum Radioprotector -- Kouvaris et al. 12 (6): 738 -- The Oncologist

Gynecologic Oncology : Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma



ScienceDirect - Gynecologic Oncology : Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma

Gynecologic Oncology : Defining practice patterns in Gynecologic Oncology to prevent pulmonary embolism and deep venous thrombosis



ScienceDirect - Gynecologic Oncology : Defining practice patterns in Gynecologic Oncology to prevent pulmonary embolism and deep venous thrombosis

Gynecologic Oncology : A new frontier for quality of care in gynecologic oncology surgery: Multi-institutional assessment of short-ter



ScienceDirect - Gynecologic Oncology : A new frontier for quality of care in gynecologic oncology surgery: Multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model

Saturday, June 16, 2007

Wednesday, June 06, 2007

Is Telik Insane?



Is Telik Insane?

ICON7 : A randomised, two arm, multi-centre Gynaecologic Cancer InterGroup phase III trial



ICON7 : A randomised, two arm, multi-centre Gynaecologic Cancer InterGroup phase III trial

Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Meno



Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Meno

2007 Abstract Study of symptoms in terminally ill patients with ovarian carcinoma



HighWire Press -- Medline Abstract

2007 Telik Reports Cancer Patients Die Sooner on Its Drug - Telcyta



Bloomberg.com: Worldwide

Should healthcare providers have a duty to warn family members of individuals with an HNPCC-causing mutation? A survey of patients from the Ontario Fa



Should healthcare providers have a duty to warn family members of individuals with an HNPCC-causing mutation? A survey of patients from the Ontario Familial Colon Cancer Registry -- Kohut et al. 44 (6): 404 -- Journal of Medical Genetics

2Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer) -- Vasen et al. 44 (6): 353 -- Journal of Medical Genetics



Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer) -- Vasen et al. 44 (6): 353 -- Journal of Medical Genetics

Table 2 Lifetime risk of cancer reported in families with an identified mismatch repair mutation

Colorectal cancer (men) 28–75%
Colorectal cancer (women) 24–52%
Endometrial cancer 27–71%
Ovarian cancer 3–13%
Gastric cancer 2–13%
Urinary tract cancer 1–12%
Brain tumour 1–4%
Bile duct/gallbladder cancer 2%
Small-bowel cancer 4–7%

2007 Exogenous hormones and colorectal cancer risk in Canada: associations stratified by clinically defined familial risk of cancer - Mount Sinai



Exogenous hormones and colorectal cancer risk in C...[Cancer Causes Control. 2007] - PubMed Result

Saturday, June 02, 2007

Health Affairs Blog - Patient Safety



The bottom line, according to Groopman, is that doctors often don’t ask the right questions and don’t listen carefully enough when the patient answers. Expect to hear more about this. The blogs are already buzzing.


Health Affairs Blog: "The bottom line, according to Groopman, is that doctors often don’t ask the right questions and don’t listen carefully enough when the patient answers. Expect to hear more about this. The blogs are already buzzing."